Compare AAME & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AAME | MAIA |
|---|---|---|
| Founded | 1968 | 2018 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.0M | 49.3M |
| IPO Year | N/A | N/A |
| Metric | AAME | MAIA |
|---|---|---|
| Price | $2.90 | $2.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.2K | ★ 1.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.25 | $0.87 |
| 52 Week High | $3.71 | $3.19 |
| Indicator | AAME | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 61.26 | 53.42 |
| Support Level | $2.51 | $1.83 |
| Resistance Level | $2.64 | $2.03 |
| Average True Range (ATR) | 0.13 | 0.23 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 95.28 | 36.45 |
Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.